phospho-CDKN1A/p21 (Ser146)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 5239R
英文名称phospho-CDKN1A/p21 (Ser146)
中文名称磷酸化p21蛋白抗体
别 名CDKN1A/p21 (phospho Ser146); CDKN1A/p21 (phospho S146); p21 (phospho Ser146); Activating Fragment 1; CAP20; Cation chloride cotransporter-interacting protein 1; CDK Interacting Protein 1; CDK-interacting protein 1; CDKI; CDKN 1; CDKN1; CDKN1A; CIP1; Cyclin Dependent Kinase Inhibitor 1A; Cyclin-dependent kinase inhibitor 1; Cyclin-dependent kinase inhibitor 1A (P21); Cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA Synthesis Inhibitor; MDA 6; MDA-6; MDA6; Melanoma Differentiation Associated Protein 6; Melanoma differentiation-associated protein 6; Melanoma differentiation-associated protein; p21; P21 protein; p21CIP1; p21WAF; PIC1; SDI1; SLC12A9; WAF1; Wildtype p53 Activating Fragment 1; Wildtype p53-activated fragment 1; CDN1A_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 信号转导
抗体来源Rabbit
克隆类型Polyclonal
phospho-CDKN1A/p21 (Ser146)抗体交叉反应 Human, Dog, Pig, Cow, Sheep, Guinea Pig, G
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量18kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CDKN1A around the phosphorylation site of Ser146 [QT(p-S)MT]:QT(p-S)MT
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CDKN1A/p21 (Ser146)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. Two families of cyclin dependent kinase inhibitors (CKIs) have been identified. The p21WAF1/Cip1 family inhibits all kinases involved in the G1/S transition. The p16INK4a family inhibits Cdk4 and Cdk6 specifically.
Function:
May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex.
Subunit:
Interacts with HDAC1; the interaction is prevented by competitive binding of C10orf90/FATS to HDAC1 facilitating acetylation and protein stabilization of CDKN1A/p21. Interacts with MKRN1. Interacts with PSMA3. Interacts with PCNA. Component of the ternary complex, cyclin D-CDK4-CDKN1A. Interacts (via its N-terminal domain) with CDK4; the interaction promotes the assembly of the cyclin D-CDK4 complex, its nuclear translocation and promotes the cyclin D-dependent enzyme activity of CDK4. Binding to CDK2 leads to CDK2/cyclin E inactivation at the G1-S phase DNA damage checkpoint, thereby arresting cells at the G1-S transition during DNA repair. Interacts with PIM1.
phospho-CDKN1A/p21 (Ser146)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CDKN1A/p21 (Ser146)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 ZNF365 锌指蛋白365抗体
合格 NR3C2/Mineralocorticoid receptor 盐皮质**受体抗体
合格 ZNF699 锌指蛋白699抗体
合格 ZNF642 锌指蛋白642抗体
合格 ZFAND2B 锌指蛋白AN1-2B抗体
合格 ZFP14 锌指蛋白14抗体
合格 ZFP161 锌指蛋白161抗体
合格 ZC4H2 ZC4H2蛋白抗体
合格 PIP5K2B 磷脂酰肌醇-5-磷酸盐-4激酶2型β抗体
合格 CLEC16A C型凝集素结构域家族16成员A抗体
合格 CCK4/PTK7 蛋白酪氨酸激酶7抗体
合格 MACF1/ACF7 肌动蛋白交联蛋白家族7抗体
合格 ZCCHC18 ZCCHC18蛋白抗体
合格 MMP12 基质金属蛋白酶-12抗体
合格 ZCCHC4 ZCCHC4蛋白抗体
合格 ZCCHC5 ZCCHC5蛋白抗体
合格 ZCCHC6 ZCCHC6蛋白抗体
合格 ZCCHC7 ZCCHC7蛋白抗体
合格 ZCCHC16 ZCCHC16蛋白抗体
合格 MAB21L1 MAB21L1蛋白抗体
合格 ZCCHC9 ZCCHC9蛋白抗体
合格 ZCPW1 ZCPW1蛋白抗体
合格 Netrin 1 轴突导向因子1抗体
合格 LYZL2 溶菌酶样蛋白2抗体
合格 LZTR2 亮氨酸拉链样转录调节因子1抗体
合格 LZTS2 亮氨酸拉链抑癌蛋白2抗体
合格 SARDH 肌氨酸脱氢酶抗体
合格 CRLR 降钙素基因相关肽1型受体抗体
合格 MAFF 转录因子MAFF抗体
合格 MAGEA6 黑色素瘤相关抗原6抗体
合格 MAGEB10 黑色素瘤相关抗原B10抗体
合格 MAGED2 黑色素瘤相关抗原D2抗体